MA39055B1 - Nouveaux dérivés d'aminopyrimidine - Google Patents

Nouveaux dérivés d'aminopyrimidine

Info

Publication number
MA39055B1
MA39055B1 MA39055A MA39055A MA39055B1 MA 39055 B1 MA39055 B1 MA 39055B1 MA 39055 A MA39055 A MA 39055A MA 39055 A MA39055 A MA 39055A MA 39055 B1 MA39055 B1 MA 39055B1
Authority
MA
Morocco
Prior art keywords
aminopyrimidine derivatives
diseases
novel
new
btk
Prior art date
Application number
MA39055A
Other languages
English (en)
Other versions
MA39055A1 (fr
Inventor
Daniela Angst
François Gessier
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39055A1 publication Critical patent/MA39055A1/fr
Publication of MA39055B1 publication Critical patent/MA39055B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Cette invention concerne de nouveaux dérivés d'aminopyrimidine de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci qui s'avèrent interagir avec la tyrosine kinase de bruton (btk). Ainsi, ces nouvelles aminopyrimidines peuvent être efficaces pour traiter les troubles auto-immuns, les maladies inflammatoires, les maladies allergiques, les maladies des voies aériennes telles que l'asthme et la broncho-pneumopathie chronique obstructive (bpco), le rejet de greffe, et les cancers, par exemple d'origine hématopoïétique, ou les tumeurs solides.
MA39055A 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine MA39055B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine

Publications (2)

Publication Number Publication Date
MA39055A1 MA39055A1 (fr) 2018-02-28
MA39055B1 true MA39055B1 (fr) 2018-10-31

Family

ID=49674216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39055A MA39055B1 (fr) 2013-11-29 2014-11-28 Nouveaux dérivés d'aminopyrimidine

Country Status (42)

Country Link
US (6) US9512084B2 (fr)
EP (5) EP3689865B1 (fr)
JP (2) JP6342495B2 (fr)
KR (2) KR102421388B1 (fr)
CN (2) CN105683181B (fr)
AP (1) AP2016009158A0 (fr)
AR (1) AR098549A1 (fr)
AU (1) AU2014356069B2 (fr)
BR (1) BR112016010397B1 (fr)
CA (1) CA2926908C (fr)
CL (1) CL2016001055A1 (fr)
CR (1) CR20160244A (fr)
CU (1) CU24384B1 (fr)
CY (3) CY1119705T1 (fr)
DK (3) DK3074386T3 (fr)
EA (1) EA031218B1 (fr)
EC (1) ECSP16054826A (fr)
ES (4) ES2947770T3 (fr)
FI (1) FI3689865T3 (fr)
HR (3) HRP20230585T1 (fr)
HU (3) HUE037588T2 (fr)
IL (1) IL244943B (fr)
JO (1) JO3314B1 (fr)
LT (3) LT3074386T (fr)
MA (1) MA39055B1 (fr)
MX (1) MX367911B (fr)
MY (2) MY191381A (fr)
NO (1) NO3074386T3 (fr)
NZ (1) NZ718835A (fr)
PE (1) PE20160869A1 (fr)
PH (1) PH12016500791B1 (fr)
PL (3) PL3074386T3 (fr)
PT (3) PT3689865T (fr)
RS (3) RS64275B1 (fr)
SI (3) SI3074386T1 (fr)
SV (1) SV2016005206A (fr)
TN (1) TN2016000128A1 (fr)
TW (1) TWI652261B (fr)
UA (1) UA117256C2 (fr)
UY (1) UY35858A (fr)
WO (1) WO2015079417A1 (fr)
ZA (1) ZA201602275B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014530A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (fr) 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
WO2017106656A1 (fr) 2015-12-17 2017-06-22 Novartis Ag Molécules d'anticorps anti-pd-1 et leurs utilisations
EP3393504B1 (fr) 2015-12-22 2025-09-24 Novartis AG Récepteur antigénique chimérique (car) spécifique contre mesotheline et anticorp contre pd-l1 à utiliser combinés dans la thérapie contre le cancer
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
EP3487878A4 (fr) 2016-07-20 2020-03-25 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation
EP3523331A1 (fr) 2016-10-07 2019-08-14 Novartis AG Récepteurs antigéniques chimériques pour le traitement du cancer
BR112019011065A2 (pt) 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
EP3644721A1 (fr) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Modèle murin pour évaluer des toxicités associées à des immunothérapies
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
AU2018358067A1 (en) 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
WO2019089858A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
WO2019118937A1 (fr) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (fr) 2018-05-25 2021-04-14 Novartis AG Polythérapie comprenant des thérapies par récepteur antigénique chimérique (car)
CA3100724A1 (fr) 2018-06-13 2019-12-19 Novartis Ag Recepteurs antigenes chimeres de la proteine de l'antigene de maturation des lymphocytes b (bcma) et utilisations connexes
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
US12024520B2 (en) 2018-08-29 2024-07-02 Acerta Pharma B.V. Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
PL3886875T3 (pl) 2018-11-30 2024-09-09 Juno Therapeutics, Inc. Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
CA3123303A1 (fr) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Anticorps et recepteurs antigeniques chimeriques specifiques du recepteur orphelin-1 de type recepteur a tyrosine kinase (ror1)
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
BR112021023054A2 (pt) * 2019-05-23 2022-03-29 Novartis Ag Formas cristalinas de um inibidor de btk
HRP20251001T1 (hr) * 2019-05-23 2025-10-24 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije
MX2021014161A (es) * 2019-05-23 2022-01-04 Novartis Ag Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
WO2020234780A1 (fr) 2019-05-23 2020-11-26 Novartis Ag Méthodes de traitement de l'asthme au moyen d'un inhibiteur de la tyrosine kinase de bruton
EP4081514A1 (fr) * 2019-12-23 2022-11-02 Biogen MA Inc. Inhibiteurs de la btk
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
MX2023001725A (es) 2020-08-14 2023-02-22 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
CN116782888A (zh) * 2021-01-26 2023-09-19 诺华股份有限公司 药物组合物
TWI905371B (zh) * 2021-01-26 2025-11-21 瑞士商諾華公司 藥物組成物
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
TW202310841A (zh) * 2021-09-03 2023-03-16 瑞士商諾華公司 用於治療多發性硬化症之ｌｏｕ０６４
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
EP4543923A1 (fr) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CA3263560A1 (fr) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Récepteurs antigéniques chimériques spécifiques de gprc5d et bcma
AU2023351959A1 (en) 2022-09-30 2025-02-27 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
TW202515850A (zh) * 2023-09-22 2025-04-16 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基類化合物、其製備方法及其在醫藥上的應用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
TW202602859A (zh) 2024-04-02 2026-01-16 瑞士商諾華公司 製備基本上不含亞硝胺雜質的瑞布替尼之方法
WO2026020055A2 (fr) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
HUP0303656A3 (en) 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
AU2002221810B2 (en) 2000-11-07 2005-06-23 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US20070185017A1 (en) 2002-10-29 2007-08-09 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006514021A (ja) 2002-12-09 2006-04-27 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法
EP1473039A1 (fr) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Utilisation d'inhibiteurs et d'oligonucleotitides antisense de BTK pour le traitement de la mastocytose proliferative
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
CA2601628C (fr) 2005-03-10 2014-05-13 Cgi Pharmaceuticals, Inc. Amides substitues, procede pour les produire et procede pour les utiliser
WO2008033858A2 (fr) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Inhibiteurs de kinase et procédés d'utilisation et d'identification des inhibiteurs de kinase
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
JP5832721B2 (ja) 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
US8426424B2 (en) 2008-05-06 2013-04-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
BRPI0913879A2 (pt) 2008-07-02 2019-09-24 Hoffmann La Roche fenilpirazinonas como inibidores de quinase
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (fr) 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2539343B1 (fr) * 2010-02-26 2015-12-30 Evotec International GmbH Thiénopyrimidines contenant un groupe alkyle substitué pour des compositions pharmaceutiques
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EP2694486B1 (fr) 2011-04-01 2018-01-10 University of Utah Research Foundation Analogues de n-(3-(pyrimidine-4-yl)phényl)acrylamide substitués en tant qu'inhibiteurs du récepteur tyrosine kinase btk
CA2836449C (fr) 2011-05-17 2021-04-27 The Regents Of The University Of California Inhibiteurs de kinase
KR20180084153A (ko) 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
CA2840413A1 (fr) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Procedes et compositions visant a inhiber la resorption osseuse
KR20140058543A (ko) 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
EP3778896A1 (fr) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
WO2013059738A2 (fr) 2011-10-19 2013-04-25 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
RU2014126750A (ru) 2011-12-09 2016-01-27 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
WO2013133367A1 (fr) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 Nouveau dérivé de triazine
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2013157021A1 (fr) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales de ceux-ci
WO2013173518A1 (fr) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2014055928A2 (fr) 2012-10-04 2014-04-10 University Of Utah Research Foundation Analogues de n-(3-(pyrimidin-4-yl)phényl) substitué utilisés en tant qu'inhibiteurs de récepteur tyrosine kinase btk
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
TN2016000128A1 (en) 2017-10-06
CN110172056B (zh) 2022-04-19
CA2926908C (fr) 2021-10-26
DK3689865T3 (en) 2023-06-19
HK1252317A1 (en) 2019-05-24
WO2015079417A1 (fr) 2015-06-04
US20180251432A1 (en) 2018-09-06
SI3689865T1 (sl) 2023-07-31
US20220041561A1 (en) 2022-02-10
HUE049794T2 (hu) 2020-10-28
CU24384B1 (es) 2019-03-04
RS64275B1 (sr) 2023-07-31
EA031218B1 (ru) 2018-12-28
AU2014356069A1 (en) 2016-05-05
US20230312483A1 (en) 2023-10-05
HUE062248T2 (hu) 2023-10-28
CN105683181A (zh) 2016-06-15
BR112016010397A8 (pt) 2020-04-22
TW201609666A (zh) 2016-03-16
JP2016538313A (ja) 2016-12-08
EP4219478A1 (fr) 2023-08-02
EP4606377A2 (fr) 2025-08-27
PL3689865T3 (pl) 2023-07-31
JP6667573B2 (ja) 2020-03-18
HRP20171999T1 (hr) 2018-02-09
HUE037588T2 (hu) 2018-09-28
LT3299368T (lt) 2020-05-25
EA201691125A1 (ru) 2016-09-30
HRP20230585T1 (hr) 2023-09-01
CY1126056T1 (el) 2023-11-15
CY1122924T1 (el) 2021-10-29
EP3689865A1 (fr) 2020-08-05
JO3314B1 (ar) 2019-03-13
SV2016005206A (es) 2016-11-21
PL3299368T3 (pl) 2020-08-10
MY179059A (en) 2020-10-26
SI3074386T1 (en) 2018-02-28
KR102380539B1 (ko) 2022-03-29
KR102421388B1 (ko) 2022-07-18
UY35858A (es) 2015-06-30
MY191381A (en) 2022-06-22
UA117256C2 (uk) 2018-07-10
PT3689865T (pt) 2023-06-16
CU20160078A7 (es) 2016-09-30
PH12016500791A1 (en) 2016-06-13
NO3074386T3 (fr) 2018-03-10
KR20160088877A (ko) 2016-07-26
US11180460B2 (en) 2021-11-23
LT3689865T (lt) 2023-07-10
ES2655527T3 (es) 2018-02-20
SI3299368T1 (sl) 2020-07-31
LT3074386T (lt) 2017-12-27
NZ718835A (en) 2021-12-24
US20160235746A1 (en) 2016-08-18
PH12016500791B1 (en) 2016-06-13
BR112016010397B1 (pt) 2023-04-11
ES2791525T3 (es) 2020-11-04
US9512084B2 (en) 2016-12-06
RS60251B1 (sr) 2020-06-30
PT3299368T (pt) 2020-05-28
RS56657B1 (sr) 2018-03-30
AU2014356069B2 (en) 2017-06-15
ES3040769T3 (en) 2025-11-04
EP3074386A1 (fr) 2016-10-05
MX2016006908A (es) 2016-08-17
PL3074386T3 (pl) 2018-03-30
PE20160869A1 (es) 2016-09-08
CA2926908A1 (fr) 2015-06-04
CY1119705T1 (el) 2018-06-27
HK1223368A1 (en) 2017-07-28
MA39055A1 (fr) 2018-02-28
AP2016009158A0 (en) 2016-04-30
DK3299368T3 (da) 2020-05-25
EP3299368A1 (fr) 2018-03-28
HRP20200775T1 (hr) 2020-07-24
TWI652261B (zh) 2019-03-01
US10457647B2 (en) 2019-10-29
EP3689865B1 (fr) 2023-03-29
ZA201602275B (en) 2017-08-30
MX367911B (es) 2019-09-11
CL2016001055A1 (es) 2016-10-28
ECSP16054826A (es) 2017-10-31
KR20220044370A (ko) 2022-04-07
JP2018141005A (ja) 2018-09-13
DK3074386T3 (en) 2018-01-22
PT3074386T (pt) 2017-11-15
US20200010426A1 (en) 2020-01-09
AR098549A1 (es) 2016-06-01
CN110172056A (zh) 2019-08-27
IL244943B (en) 2020-04-30
EP3299368B1 (fr) 2020-02-26
CR20160244A (es) 2016-07-29
US20150152068A1 (en) 2015-06-04
CN105683181B (zh) 2019-04-23
US11673868B2 (en) 2023-06-13
EP4219478B1 (fr) 2025-06-11
EP3074386B1 (fr) 2017-10-11
IL244943A0 (en) 2016-05-31
EP4606377A3 (fr) 2025-11-26
ES2947770T3 (es) 2023-08-18
JP6342495B2 (ja) 2018-06-13
FI3689865T3 (fi) 2023-06-12

Similar Documents

Publication Publication Date Title
MA39055B1 (fr) Nouveaux dérivés d'aminopyrimidine
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
MA35285B1 (fr) Indazoles
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA41625A (fr) Composés de benzazépine dicarboxamide
BR112015021888A2 (pt) inibidores de dna-ik
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
BR112017011798A2 (pt) 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
BR112015014701A2 (pt) derivados de benzimidazol como inibidores de quinase
EP4275756A3 (fr) Dérivés de bipyrazole servant d'inhibiteurs de jak
DE602007008434D1 (de) Rezeptoren
EA201270561A1 (ru) Антагонисты рецептора cgrp
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
EA201790072A1 (ru) Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы
EA201890769A1 (ru) Производные 2,3,4,5-тетрагидропиридин-6-амина